Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system

Kyoko Mori, Masanori Ikeda, Yasuo Ariumi, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. We investigated the anti-HCV activity of RBV using novel cell assay systems. The recently discovered human hepatoma cell line, Li23, which enables robust HCV replication, and the recently developed Li23-derived drug assay systems (ORL8 and ORL11), in which the genome-length HCV RNA (O strain of genotype 1b) encoding renilla luciferase efficiently replicates, were used for this study. At clinically achievable concentrations, RBV unexpectedly inhibited HCV RNA replication in ORL8 and ORL11 systems, but not in OR6 (an HuH-7-derived assay system). The anti-HCV activity of RBV was almost cancelled by an inhibitor of equilibrative nucleoside transporters. The evaluation of the anti-HCV mechanisms of RBV proposed to date using ORL8 ruled out the possibility that RBV induces error catastrophe, the IFN-signaling pathway or oxidative stress. However, we found that the anti-HCV activity of RBV was efficiently cancelled with guanosine, and demonstrated that HCV RNA replication was notably suppressed in inosine monophosphate dehydrogenase (IMPDH)-knockdown cells, suggesting that the antiviral activity of RBV is mediated through the inhibition of IMPDH. In conclusion, we demonstrated for the first time that inhibition of IMPDH is a major antiviral target by which RBV at clinically achievable concentrations inhibits HCV RNA replication.

Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalVirus Research
Volume157
Issue number1
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Ribavirin
Virus Replication
Hepacivirus
Inosine Monophosphate
RNA
Oxidoreductases
Interferons
Antiviral Agents
Renilla Luciferases
Nucleoside Transport Proteins
Guanosine
Chronic Hepatitis C
Hepatocellular Carcinoma
Oxidative Stress
Cell Culture Techniques
Genotype
Genome

Keywords

  • HCV
  • HCV RNA replication system
  • IMPDH inhibitor
  • RBV

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Cancer Research

Cite this

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. / Mori, Kyoko; Ikeda, Masanori; Ariumi, Yasuo; Dansako, Hiromichi; Wakita, Takaji; Kato, Nobuyuki.

In: Virus Research, Vol. 157, No. 1, 04.2011, p. 61-70.

Research output: Contribution to journalArticle

Mori, Kyoko ; Ikeda, Masanori ; Ariumi, Yasuo ; Dansako, Hiromichi ; Wakita, Takaji ; Kato, Nobuyuki. / Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. In: Virus Research. 2011 ; Vol. 157, No. 1. pp. 61-70.
@article{700b81dddf7c409ca97eb48d86034351,
title = "Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system",
abstract = "Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. We investigated the anti-HCV activity of RBV using novel cell assay systems. The recently discovered human hepatoma cell line, Li23, which enables robust HCV replication, and the recently developed Li23-derived drug assay systems (ORL8 and ORL11), in which the genome-length HCV RNA (O strain of genotype 1b) encoding renilla luciferase efficiently replicates, were used for this study. At clinically achievable concentrations, RBV unexpectedly inhibited HCV RNA replication in ORL8 and ORL11 systems, but not in OR6 (an HuH-7-derived assay system). The anti-HCV activity of RBV was almost cancelled by an inhibitor of equilibrative nucleoside transporters. The evaluation of the anti-HCV mechanisms of RBV proposed to date using ORL8 ruled out the possibility that RBV induces error catastrophe, the IFN-signaling pathway or oxidative stress. However, we found that the anti-HCV activity of RBV was efficiently cancelled with guanosine, and demonstrated that HCV RNA replication was notably suppressed in inosine monophosphate dehydrogenase (IMPDH)-knockdown cells, suggesting that the antiviral activity of RBV is mediated through the inhibition of IMPDH. In conclusion, we demonstrated for the first time that inhibition of IMPDH is a major antiviral target by which RBV at clinically achievable concentrations inhibits HCV RNA replication.",
keywords = "HCV, HCV RNA replication system, IMPDH inhibitor, RBV",
author = "Kyoko Mori and Masanori Ikeda and Yasuo Ariumi and Hiromichi Dansako and Takaji Wakita and Nobuyuki Kato",
year = "2011",
month = "4",
doi = "10.1016/j.virusres.2011.02.005",
language = "English",
volume = "157",
pages = "61--70",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system

AU - Mori, Kyoko

AU - Ikeda, Masanori

AU - Ariumi, Yasuo

AU - Dansako, Hiromichi

AU - Wakita, Takaji

AU - Kato, Nobuyuki

PY - 2011/4

Y1 - 2011/4

N2 - Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. We investigated the anti-HCV activity of RBV using novel cell assay systems. The recently discovered human hepatoma cell line, Li23, which enables robust HCV replication, and the recently developed Li23-derived drug assay systems (ORL8 and ORL11), in which the genome-length HCV RNA (O strain of genotype 1b) encoding renilla luciferase efficiently replicates, were used for this study. At clinically achievable concentrations, RBV unexpectedly inhibited HCV RNA replication in ORL8 and ORL11 systems, but not in OR6 (an HuH-7-derived assay system). The anti-HCV activity of RBV was almost cancelled by an inhibitor of equilibrative nucleoside transporters. The evaluation of the anti-HCV mechanisms of RBV proposed to date using ORL8 ruled out the possibility that RBV induces error catastrophe, the IFN-signaling pathway or oxidative stress. However, we found that the anti-HCV activity of RBV was efficiently cancelled with guanosine, and demonstrated that HCV RNA replication was notably suppressed in inosine monophosphate dehydrogenase (IMPDH)-knockdown cells, suggesting that the antiviral activity of RBV is mediated through the inhibition of IMPDH. In conclusion, we demonstrated for the first time that inhibition of IMPDH is a major antiviral target by which RBV at clinically achievable concentrations inhibits HCV RNA replication.

AB - Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. We investigated the anti-HCV activity of RBV using novel cell assay systems. The recently discovered human hepatoma cell line, Li23, which enables robust HCV replication, and the recently developed Li23-derived drug assay systems (ORL8 and ORL11), in which the genome-length HCV RNA (O strain of genotype 1b) encoding renilla luciferase efficiently replicates, were used for this study. At clinically achievable concentrations, RBV unexpectedly inhibited HCV RNA replication in ORL8 and ORL11 systems, but not in OR6 (an HuH-7-derived assay system). The anti-HCV activity of RBV was almost cancelled by an inhibitor of equilibrative nucleoside transporters. The evaluation of the anti-HCV mechanisms of RBV proposed to date using ORL8 ruled out the possibility that RBV induces error catastrophe, the IFN-signaling pathway or oxidative stress. However, we found that the anti-HCV activity of RBV was efficiently cancelled with guanosine, and demonstrated that HCV RNA replication was notably suppressed in inosine monophosphate dehydrogenase (IMPDH)-knockdown cells, suggesting that the antiviral activity of RBV is mediated through the inhibition of IMPDH. In conclusion, we demonstrated for the first time that inhibition of IMPDH is a major antiviral target by which RBV at clinically achievable concentrations inhibits HCV RNA replication.

KW - HCV

KW - HCV RNA replication system

KW - IMPDH inhibitor

KW - RBV

UR - http://www.scopus.com/inward/record.url?scp=79953025461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953025461&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2011.02.005

DO - 10.1016/j.virusres.2011.02.005

M3 - Article

C2 - 21320556

AN - SCOPUS:79953025461

VL - 157

SP - 61

EP - 70

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 1

ER -